Stifel reiterates Medtronic stock rating on renal denervation growth

Financial services firm Stifel has reaffirmed its 'Buy' rating for Medtronic (NYSE: MDT) stock, citing strong projected growth for the company's renal denervation therapy platform. The analyst action, communicated to investors in a research note published on January 15, 2025, is based on an optimistic outlook for the medical device giant's Symplicity Spyral system, which treats hypertension by disrupting nerve signals to the kidneys. This endorsement highlights growing confidence in a key pipeline product expected to drive future revenue. The reiteration comes at a pivotal time for Medtronic's renal denervation business. The Symplicity Spyral system, which received U.S. Food and Drug Administration (FDA) approval in late 2023, addresses a massive and largely untreated patient population suffering from resistant hypertension. Stifel's analysis suggests the therapy is moving beyond initial adoption phases and is poised for significant market penetration, representing a substantial long-term growth driver for the Dublin-based company amidst a competitive and innovation-driven medtech landscape. This analyst confidence is underpinned by recent clinical data and commercial execution. Medtronic has reported strong real-world evidence supporting the therapy's efficacy and safety, which bolsters reimbursement cases with insurers and adoption among physicians. The firm's rating implies that the renal denervation franchise could meaningfully offset pressures in other slower-growth segments of Medtronic's portfolio, such as certain cardiac rhythm or spinal devices, thereby supporting overall stock valuation. The move signals to the market that Medtronic's strategic investment in this advanced therapy is beginning to yield expected returns.